Despite being a risk factor for multiple cancers, obesity paradoxically enhances the efficacy of ICI therapies, potentially due to higher PD-1 expression on exhausted CD8 + T cells, making them more responsive to PD-1 inhibitors [27]. The gene discussed is CD8A; the disease is obesity due to melanocortin 4 receptor deficiency.